Vabysmo (faricimab-svoa) for Diabetes

Overview 
Vabysmo is a prescription drug approved by the U.S. Food and Drug Administration (FDA) for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Vabysmo is also referred to by its drug name, faricimab-svoa. 

Vabysmo is a humanized bispecific antibody. This means that it is a type of medication that mimics antibodies found in humans and can target two different things at once. It works by blocking two pathways that contribute to the progression of nAMD and DME. Specifically, it binds the proteins called vascular endothelial growth factor A and angiopoietin-2.  

How do I take it? 
Prescribing information states that Vabysmo is available as an intravitreal injection, meaning it is injected into the eye by a medical professional. Injections are given every four weeks for the first four doses and then may be given at less frequent intervals. 

Side effects 
The FDA-approved label for Vabysmo lists the only common side effect as conjunctival hemorrhage. There is a lower risk of other adverse reactions such as retinal detachment, increased intraocular (inside the eye) pressure, and blood clots. 

For more details about this treatment, visit: 

Vabysmo — Genentech
https://www.vabysmo.com/

Vabysmo — Faricimab Injection, Solution — DailyMed
https://dailymed.nlm.nih.gov/dailymed/lookup.cf...

Efficacy, Durability, and Safety of Faricimab up to Every 16 Weeks In Patients With Neovascular Age-Related Macular Degeneration: 1-Year Results From The Japan Subgroup Of The Phase 3 TENAYA Trial — Japanese Journal of Ophthalmology
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10...